diabetestalk.net

ADA: Cardiovascular Benefits Seen With Long-Term Metformin Use In Adults With Type 1 Diabetes

ADA: Cardiovascular Benefits seen with Long-Term Metformin Use in Adults with Type 1 Diabetes

ADA: Cardiovascular Benefits seen with Long-Term Metformin Use in Adults with Type 1 Diabetes


Home / Conditions / Type 1 Diabetes / ADA: Cardiovascular Benefits seen with Long-Term Metformin Use in Adults with Type 1 Diabetes
ADA: Cardiovascular Benefits seen with Long-Term Metformin Use in Adults with Type 1 Diabetes
Results from the REMOVAL trial revealed reduction in the risk of cardiovascular disease among other benefits with metformin in type 1 diabetes patients.
Atherosclerosis leads to macrovascular complications in diabetes. These complications contribute to the majority of deaths in patients with diabetes. The use of metformin in previous studies have established a reduction in risk of cardiovascular disease in patients with type 2 diabetes. This is one of the reasons why metformin is currently recommended as first line therapy for these patients. However, it is only recommended for off label use in overweight or obese patients with type 1 diabetes to assist in weight loss and to decrease insulin dose requirements. Researchers wanted to investigate the potential use of metformin in patients with type 1 diabetes, to evaluate if these patients could also benefit from the reduction in risk of cardiovascular disease.
An international, double-blind study called the REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) study enrolled 493 participants over the age of 40 with a minimum of five year duration of type 1 diabetes and at least three cardiovascular risk factors. The ten defined risk factors in the study include known CVD, strong family history of CVD, diabetes duration > 20 years, a BMI 28 kg/m2, HbA1c > 8.0%, current smoker, microalbuminuria Continue reading

Rate this article
Total 1 ratings
News Alert: Blink Health To Give Away $10 Million Worth Of Free Diabetes Medications To Help People Afford Treatment

News Alert: Blink Health To Give Away $10 Million Worth Of Free Diabetes Medications To Help People Afford Treatment

NEW YORK, June 7, 2017 /PRNewswire/ -- Blink Health, America's leading prescription drug savings platform, today launched a program to help #TreatType2 diabetes by committing to give away $10 million worth of medication to patients with type-2 diabetes. People living with diabetes who create an account on Blink Health's website or free mobile app, starting today, will receive a free, one-year supply of the three most commonly prescribed generic medications for type-2 diabetes: metformin, glipizide and pioglitazone. The program will also cover these three medications for existing Blink Health patients who use them.
Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8117451-blink-health-type-2-diabetes-medications/
As part of Blink Health's ongoing commitment to support people who are living with diabetes, the #TreatType2 program is designed to help the largest population of people managing this condition. Of the nearly 29 million Americans with diabetes, approximately 95 percent have been diagnosed with type 2.1
Blink Health will provide the free medications to everyone until it has committed to spending $10 million on the medications. Any patient with a prescription for any or all of these three medications is eligible to receive medication for free. There is no cost to join Blink Health, and medication can be picked up at over 57,000 pharmacies nationwide, including Walmart, CVS, Rite-Aid, Target, and most independent pharmacies and grocers.
The $10 million commitment is based on Blink's cost to purchase the medication and re Continue reading

Symptoms at Diagnosis May Predict Progression of Type 2 Diabetes

Symptoms at Diagnosis May Predict Progression of Type 2 Diabetes

Researchers followed patients who were newly diagnosed with type 2 diabetes for 18 months to classify their disease progression based on 20 baseline symptoms.
With Caroline A. Brorsson, PhD, and Michael Gonzalez-Campoy, MD, PhD
Three major subgroups of newly diagnosed patients with type 2 diabetes (T2D) experienced different rates of disease progression over 18 months,1 according to data presented at the 53rd annual meeting of the European Association for the Study of Diabetes in Lisbon, Portugal. The research was part of the Diabetes Research on Patient Stratification project (DIRECT) within the European Union Framework 7 Innovative Medicines Initiative.
Patients with type 2 diabetes are likely to present with varying degrees of insulin resistance and beta cell failure.1 Understanding the heterogeneity of a T2D presentation may lead to more effective treatment strategies for these patients. An underlying difference in pathophysiology may be indicative of a patient’s responsiveness to a prescribed treatment and have an anticipated effect on disease progression.1
Evaluating Differences in Diabetes Progression
Caroline Brorsson, PhD, a postdoctoral researcher at the Technical University of Denmark and colleagues used the detailed clinical phenotyping from the Diabetes Remission Clinical Trial (DIRECT) to identify and cluster subgroups of patients who were newly diagnosed with T2D.1,2 In the DIRECT study, detailed metabolic data were collected on patients newly diagnosed with either prediabetes or type 2 diabetes.2
“Using a very detailed clinical phenotyping methodology, w Continue reading

Berberine: A Supplement for Diabetes as Good as a Drug?

Berberine: A Supplement for Diabetes as Good as a Drug?


Berberine: A Supplement for Diabetes as Good as a Drug?
Berberine: A Supplement for Diabetes as Good as a Drug?
The Centers for Disease Control and Prevention (CDC) has declared diabetes an American epidemic with more than 25 million Americans afflicted with diabetes. Another 80 million are classified prediabetic, per the American Diabetes Association. The numbers get even bigger when you put a dollar sign in front of them: As of 2012, $245 billion a year was being spent on diabetes in the U.S., including $176 billion in direct medical costs and the rest -- $69 billion in lost productivity.
Its no wonder that pharmaceutical companies remain fully engaged in diabetes-related research, devising new medications and enhancing the older ones looking for a cure. Among the drugs now being used for type 2 diabetes are metformin, sulfonylureas (which goes by the trade names Diabeta and Glucotrol, among others) and DPP-5 inhibitors (Januvia, Tradienta, etc.). All have been shown to be effective to one degree or another, but the epidemic continues to beg for new and improved drugs.
One of the great new hopes in the world of diabetes treatment is a natural plant-based compound that has been used for thousands of years in traditional Chinese and Ayurvedic medical practice. However, it has only become a part of Western medicine in recent years. Most of the attention on berberine, at least in the U.S., encompasses only the 21st century. In that sense, our newest discovery means we are just now catching up with the rest of the world.
Note to readers: Wonder Labs will have a special Continue reading

Long-Term Benefits of Linoleic Acid In Type 2 Diabetes

Long-Term Benefits of Linoleic Acid In Type 2 Diabetes


Home / Conditions / Type 2 Diabetes / Long-Term Benefits of Linoleic Acid In Type 2 Diabetes
Long-Term Benefits of Linoleic Acid In Type 2 Diabetes
High linoleic acid level could reduce type 2 risk by 43 percent, new study found.
Polyunsaturated fatty acids such as omega-3 and omega-6 fatty acids are beneficial for improving lipid profiles in healthy individuals and among patients with type 2 diabetes.
Supplementation with omega-3 fatty acids lowers triglycerides and VLDL cholesterol, but they might also increase LDL cholesterol. Latest evidences suggest omega-3 fatty acids are not related to mortality, hypertension, cardiovascular disease as well as the risk of microvascular complications in patients with type 2 diabetes. Meanwhile, the metabolic effects of omega-6 fatty acids remain largely unknown and there is little available evidence regarding their potential role in the prevention of type 2 diabetes. A pooled analysis of international studies was assessed to find the associations of linoleic acid and arachidonic acid biomarkers with incident type 2 diabetes.
Researchers analyzed data from 20 prospective cohort studies from ten countries, including Iceland, Netherlands, United States, Taiwan, United Kingdom, Germany, Finland, Australia, Sweden, and France. All included study participants were between 49-76 years old with a body mass index of 23.328.4 kg/m2 and had data for linoleic acid and arachidonic acid biomarkers at baseline. Any participants with type 2 diabetes at baseline were excluded from the study. Researchers defined incident type 2 diabetes as havin Continue reading

No more pages to load

Popular Articles

Related Articles